Agios Pharmaceuticals, Inc. – Acute Myeloid Leukemia

Access Program Information

To provide access to ivosidenib monotherapy to patients with relapsed or refractory acute
myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation.